ArticleGland surgery2022
Escaping sestamibi detection: a case report of aggressive and recurrent metastatic parathyroid carcinoma.
Article in Gland surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Preoperative Clinical Prediction of Parathyroid Carcinoma: Two Rare Case Presentations and a Review of Literature.The American journal of case reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parathyroid carcinoma is exceedingly rare. This cancer does not metastasize in a predictable manner and has in fact been noted to spread both hematogenously and lymphatically. There are currently no cases in the literature that report metastasis to a contralateral level II lymph node. Case Description: We report a case of recurrent parathyroid carcinoma in which the patient underwent several surgeries for right-sided parathyroid carcinoma and hyperparathyroidism, including 2 redo parathyroidectomies, 4 neck dissections, and auto transplantation and re-excision of the autotransplanted tissue. Almost a decade after initial surgery, parathyroid hormone (PTH) levels rose significantly, but nuclear medicine (NM) sestamibi scan, positron emission tomography-computed tomography (PET-CT), and ultrasound (US) could not identify the source of recurrent disease. Finally, neck US revealed a suspicious contralateral level II lymph node; fine needle aspiration (FNA) of the lymph node revealed parathyroid tissue, and PTH aspirate noted an elevated PTH washout. After left lateral neck dissection, pathology confirmed recurrent metastatic parathyroid carcinoma, and serum calcium and PTH levels improved. This case was further complicated by chronic kidney disease and pT1N0M0 colon cancer, all before the age of 45. Conclusions: In cases where a sestamibi scan is not able to localize a metastatic focus in a patient with known parathyroid carcinoma, FNA and PTH washout are important secondary studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.